CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Jacob P Laubach; Paul G Richardson

doi:10.1158/1078-0432.CCR-14-3190

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Clin Cancer Res. 2015 Jun 15;21(12):2660-2. doi: 10.1158/1078-0432.CCR-14-3190. Epub 2015 Apr 15.

Authors

Jacob P Laubach¹, Paul G Richardson²

Affiliations

¹ Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
² Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. paul_richardson@dfci.harvard.edu.

PMID: 25878332
DOI: 10.1158/1078-0432.CCR-14-3190

Abstract

CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors*
ADP-ribosyl Cyclase 1 / metabolism*
Animals
Bortezomib / pharmacology*
Female
Humans
Lenalidomide
Male
Multiple Myeloma / immunology*
Multiple Myeloma / metabolism*
Thalidomide / analogs & derivatives*
Thalidomide / pharmacology

Substances

Thalidomide
Bortezomib
ADP-ribosyl Cyclase 1
Lenalidomide